Main Article Content
Diabetes mellitus (DM) with pulmonary tuberculosis (TB) is an infectious disease if not educated regularly, there will be a high risk of drug resistance and even some anti-tuberculosis drugs. This study aims to identify anti-tuberculosis drug resistance in DM patients with TB in Manado City. The population in the study types 2 DM patients as amount 80 patients. Based on TCM/GenExpert examination from 47 respondents, there were 17 respondents positive multi drugs resistance rifampicin (RR). Sampling taking based on inclusion criteria, i.e., have had type DM for five years, had suffered TB MDR RR based on GenXpert examination as much as 17 respondents followed in the resistance test with Sputum TB culture and MGIT method. The result of the study showed that MDR DM-TB with MGIT method as followed is obtained from 17 samples, six samples (35.30%) resistance INH 0.4 mg and 1 sample (5.88%) MDR canamycin, and still sensitive INH 0.4 mg and camaycin is ten samples (58.82%). This study results could be used to program planning of prevention and controlling efforts TB-DM in this treatment obedience and regimen anti-tuberculosis medicine for MDR-TB patients.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
2. Song W, Shao Y, Liu J, et al. Primary drug resistance among tuberculosis patients with diabetes mellitus: a retrospective study among 7223 cases in China. Infect Drug Resist. 2019;Volume 12:2397-2407. doi:10.2147/IDR.S217044.
3. Zaragoza B, Laniado-LaborĂn R. Diagnosing Drug-Resistant Tuberculosis with the XpertÂ®MTB/RIF. The Risk for Rifampin Susceptible Cases. J Tuberc Res. 2017;05(03):155-160. doi:10.4236/jtr.2017.53017.
4. Aung MN, Moolphate, Aung M, et al. Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB. Infect Drug Resist. 2012;5(1):79. doi:10.2147/IDR.S24295
5. Siahaan AGH, Polii EBI, Ongkowijaya J. Profil pasien tuberkulosis dengan multi drug resistance (MDR). J e-Clinic. 2016;4. https://ejournal.unsrat.ac.id/index.php/eclinic/article/view/14498/14071.
6. Novianti N, Simarmata OS, Lolong DB. Pemanfaatan Tes Cepat Molekuler (TCM) Genexpert Sebagai Alat Diagnostik TB Paru di RSUD Wangaya Kota Denpasar. J Ekol Kesehat. 2020;18(3):135-148. doi:10.22435/jek.v3i18.2399.
7. Aderita NI, Murti B, Suryani N. Risk Factors Affecting Multi-Drug Resistant Tuberculosis in Surakarta and Wonogiri, Central Java, Indonesia. J Epidemiol PublicHealth. 2016;01(02):86-99. doi:10.26911/jepublichealth.2016.01.02.02.
8. Rumende CM. Risk Factors for Multidrug-resistant Tuberculosis. Acta Med Indones. 2018;50(1):1-2. http://www.ncbi.nlm.nih.gov/pubmed/29686169.
9. Mulu W, Mekkonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci. 2015;15(2):368. doi:10.4314/ahs.v15i2.9.
10. Gomes M, Correia A, MendonĂ§a D, Duarte R. Risk Factors for Drug-Resistant Tuberculosis. J Tuberc Res. 2014;02(03):111-118. doi:10.4236/jtr.2014.23014.
11. Rodal C. Tuberculosis, Enfermedad Infecciosa MĂˇs Letal En El Mundo. BoletĂn UNAM-DGCS-187bis Ciudad Univ. 2018;44(2):145-152. https://www.dgcs.unam.mx/boletin/bdboletin/2018_187bis.html.
12. Wijaya I. Tuberkulosis Paru pada Penderita Diabetes Melitus. Cermin Dunia Kedokt. 2015;42(6):412-417. http://www.cdkjournal.com/index.php/CDK/article/view/996.
13. Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. Marotta C, ed. PLoS One. 2021;16(2):e0246284. doi:10.1371/journal.pone.0246284.
14. Widyaningsih P, Nugroho AA, Saputro DRS, Sutanto. Tuberculosis transmission with relapse in Indonesia: susceptible vaccinated infected recovered model. J Phys Conf Ser. 2019;1217(1):012071. doi:10.1088/1742-6596/1217/1/012071.
15. Suen S, Bendavid E, Goldhaber-Fiebert JD. Disease Control Implications of Indiaâ€™s Changing Multi-Drug Resistant Tuberculosis Epidemic. Dowdy DW, ed. PLoS One. 2014;9(3):e89822. doi:10.1371/journal.pone.0089822.
16. Wai PP, Shewade HD, Kyaw NTT, et al. Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar. Shankar EM, ed. PLoS One. 2018;13(3):e0194087. doi:10.1371/journal.pone.0194087.
17. Hossain ST, Isaakidis P, Sagili KD, et al. The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh. Subbian S, ed. PLoS One. 2015;10(6):e0129155. doi:10.1371/journal.pone.0129155.
18. Li B-Y, Shi W-P, Zhou C-M, et al. Rising challenge of multidrug-resistant tuberculosis in China: a predictive study using Markov modeling. Infect Dis Poverty. 2020;9(1):65. doi:10.1186/s40249-020-00682-7.
19. Kendall EA, Azman AS, Cobelens FG, Dowdy DW. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. Chatterji D, ed. PLoS One. 2017;12(3):e0172748. doi:10.1371/journal.pone.0172748.